Transferring Peptide-Target Interaction Patterns to Small Molecules by Joint Guidance for Diffusion and Flow Matching

The design of high-affinity, target-specific protein binders is central to the development of modern therapeutics. However, existing protein-generation methods remain limited in this setting, as many generated designs fail to simultaneously achieve geometric and physicochemical complementarity at binding interfaces. To address this challenge, we introduce PIDiff, a physicochemically enhanced multimodal diffusion framework for protein-protein complex design. PIDiff jointly designs target-conditioned protein sequences and structures by coupling diffusion in discrete sequence space with diffusion on the continuous (SE(3)) structural manifold. At its core, PIDiff employs PIFormer, a novel architecture that interleaves geometry-aware invariant point attention with global sequence self-attention. We further curate PIBench, a protein-protein complex dataset with diverse target scaffolds derived from the Protein Data Bank (PDB). We first pretrain PIDiff on PIBench and subsequently fine-tune it for two therapeutically relevant applications: minibinder design and antibody design. PPFrame consistently outperforms baseline methods across sequence design success rate, structure binding energy, and sequence-structure co-designability on all tasks.

Motivation: Peptide-protein interactions (PepPIs) are central to cellular regulation and peptide therapeutics, but experimental characterization remains too slow for large-scale screening. Existing methods usually emphasize either interaction prediction or peptide generation, leaving candidate prioritization, residue-level interpretation, and target-conditioned expansion insufficiently integrated. Results: We present an integrated framework for early-stage peptide screening that combines a partner-aware prediction and localization model (ConGA-PepPI) with a target-conditioned generative model (TC-PepGen). ConGA-PepPI uses asymmetric encoding, bidirectional cross-attention, and progressive transfer from pair prediction to binding-site localization, while TC-PepGen preserves target information throughout autoregressive decoding via layerwise conditioning. In five-fold cross-validation, ConGA-PepPI achieved 0.839 accuracy and 0.921 AUROC, with binding-site AUPR values of 0.601 on the protein side and 0.950 on the peptide side, and remained competitive on external benchmarks. Under a controlled length-conditioned benchmark, 40.39% of TC-PepGen peptides exceeded native templates in AlphaFold 3 ipTM, and unconstrained generation retained evidence of target-conditioned signal.

Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 Å backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.